A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs AZD 3759 (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Acronyms BLOOM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 13 Oct 2017 to 3 Aug 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 According to an AstraZeneca media release, data from thsi study was presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top